Patents by Inventor Markus BRECHMANN

Markus BRECHMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089591
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: January 28, 2021
    Publication date: March 24, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexandros VAKALOPOULOS, Melissa BOULTADAKIS ARAPINIS, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximillian Andreas KULLMANN, Till FREUDENBERGER, Thomas MONDRITZKI, Tobias MARQUARDT
  • Publication number: 20210261541
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 26, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexandros VAKALOPOULOS, Melissa BOULTADAKIS ARAPINIS, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximillian Andreas KULLMANN, Till FREUDENBERGER, Thomas MONDRITZKI, Tobias MARQUARDT
  • Patent number: 10927109
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: February 23, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexandros Vakalopoulos, Melissa Boultadakis Arapinis, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximilian Andreas Kullmann, Till Freudenberger, Thomas Mondritzki, Tobias Marquardt
  • Patent number: 10519154
    Abstract: The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: December 31, 2019
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Henrik Teller, Melissa Boultadakis Arapinis, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximillian Andreas Kullmann, Klaus Münter, Thomas Mondritzki, Tobias Marquardt
  • Publication number: 20190367516
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 5, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexander STRAUB, Markus BRECHMANN, Thomas MÜLLER, Mark MEININGHAUS, Katrin NOWAK-REPPEL, Hanna TINEL, Klaus MÜNTER, Daniela FLIEGNER, Thomas MONDRITZKI, Melissa BOULTADAKIS ARAPINIS, Tobias MARQUARDT, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Matthias Beat WITTWER
  • Patent number: 10435403
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 8, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexander Straub, Markus Brechmann, Thomas Müller, Mark Meininghaus, Katrin Nowak-Reppel, Hanna Tinel, Klaus Münter, Daniela Fliegner, Thomas Mondritzki, Melissa Boultadakis Arapinis, Tobias Marquardt, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Matthias Beat Wittwer
  • Publication number: 20190263805
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: September 6, 2017
    Publication date: August 29, 2019
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexandros VAKALOPOULOS, Melissa BOULTADAKIS ARAPINIS, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximilian Andreas KULLMANN, Till FREUDENBERGER, Thomas MONDRITZKI, Tobias MARQUARDT
  • Publication number: 20190241562
    Abstract: The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: July 4, 2017
    Publication date: August 8, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Henrik TELLER, Melissa BOULTADAKIS ARAPINIS, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Alexander STRAUB, Hanna TINEL, Markus BRECHMANN, Matthias Beat WITTWER, Maximillian Andreas KULLMANN, Klaus MÜNTER, Thomas MONDRITZKI, Tobias MARQUARDT
  • Publication number: 20180297994
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: June 6, 2016
    Publication date: October 18, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexander STRAUB, Markus BRECHMANN, Thomas MÜLLER, Mark MEININGHAUS, Katrin NOWAK-REPPEL, Hanna TINEL, Klaus MÜNTER, Daniela FLIEGNER, Thomas MONDRITZKI, Melissa BOULTADAKIS ARAPINIS, Tobias MARQUARDT, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Matthias Beat WITTWER